Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region

Journal of Viral Hepatitis

Volumn 18, Issue 5, 2011, Pages 369-375

  Poovorawan, Y ^a   Chongsrisawat, V ^a   Theamboonlers, A ^a   Leroux Roels, G ^b   Kuriyakose, S ^c   Leyssen, M ^c   Jacquet, J M ^c  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

efficacy; hepatitis B; vaccine

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ARTICLE; ENDEMIC DISEASE; FEMALE; HEPATITIS B; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVACCINATION; SEROCONVERSION; VACCINATION;

ADOLESCENT; CARRIER STATE; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; ENDEMIC DISEASES; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNIZATION, SECONDARY; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LONGITUDINAL STUDIES; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; THAILAND; YOUNG ADULT;

EID: 79953861295     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01312.x     Document Type: Article

References (23)

1. World Health Organization. Hepatitis B vaccines WHO position paper. Wkly Epidemiol Rec 2004; 79: 255-263.
2. World Health Organization. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull World Health Organ 1988; 66: 443-455.
3. Poovorawan Y, Chongsrisawat V, Tangkijvanich P,. Problems and prevention of viral hepatitis in Thailand. J Med Assoc Thai 2001; 84 (Suppl 1): S18-S25. (Pubitemid 33714830)
4. Merican I, Guan R, Amarapuka D, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000; 15: 1356-1361. (Pubitemid 32052906)
5. Lolekha S, Warachit B, Hirunyachote A, Bowonkiratikachorn P, West DJ, Poerschke G,. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. Vaccine 2002; 20: 3739-3743. (Pubitemid 35223404)
6. Zanetti AR, Van Damme P, Shouval D,. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-6273.
7. Chongsrisawat V, Yoocharoen P, Theamboonlers A, et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006; 11: 1496-1502. (Pubitemid 44450554)
8. Chien YC, Jan CF, Kuo HS, Chen CJ,. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006; 28: 126-135.
9. Ng KP, Saw TL, Baki A, Rozainah K, Pang KW, Ramanathan M,. Impact of the Expanded Program of Immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol (Berl) 2005; 194: 163-168. (Pubitemid 41202533)
10. Wichajarn K, Kosalaraksa P, Wiangnon S,. Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac J Cancer Prev 2008; 9: 507-510.
11. Van Damme P, Van Herck K,. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis. 2007; 5: 79-84. (Pubitemid 46211211)
12. Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A,. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989; 261: 3278-3281. (Pubitemid 19143550)
13. Poovorawan Y, Sanpavat S, Pongpunlert W, et al. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990; 8 (Suppl): S56-S59. (Pubitemid 20154762)
14. Poovorawan Y, Sanpavat S, Chumdermpadetsuk S, Safary A,. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child Fetal Neonatal Ed 1997; 77: F47-F51. (Pubitemid 28201628)
15. Poovorawan Y, Sanpavat S, Pongpunglert W, et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992; 11: 816-821.
16. Chinchai T, Chirathaworn C, Praianantathavorn K, et al. Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization. Viral Immunol 2009; 22: 125-130.
17. Poovorawan Y, Chongsrisawat V, Theamboonlers A, Bock HL, Leyssen M, Jacquet JM,. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010; 28: 730-736.
18. Lopez VA, Bourne EJ, Lutz MW, Condreay LD,. Assessment of the COBAS Amplicor HBV Monitor Test for quantitation of serum hepatitis B virus DNA levels. J Clin Microbiol 2002; 40: 1972-1976. (Pubitemid 34596370)
19. Su FH, Cheng SH, Li CY, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25: 8085-8090.
20. Alfaleh F, Alshehri S, Alansari S, et al. Long-term protection of hepatitis B vaccine in Saudi Arabia 18 years after vaccination. J Infect 2008; 57: 404-409.
21. van der Sande MA, Waight PA, Mendy M, et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS ONE 2007; 2: e753.
22. Kao JT, Wang JH, Hung CH, et al. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine 2009; 27: 1858-1862.
23. But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF,. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008; 26: 6587-6591.